Group 1 - The core viewpoint of the news is that Shanghai Yutian Guanjia Technology Co., Ltd. experienced a decline in stock price, with a drop of 5.01% to 46.46 CNY per share, resulting in a market capitalization of 4.08 billion CNY [1] - The company specializes in manufacturing automotive sunroofs and has integrated capabilities in design, research and development, and production, primarily serving well-known domestic and international automotive manufacturers [1] - The main revenue composition of the company includes panoramic sunroofs at 65.29%, small sunroofs at 20.89%, and other products at 13.82% [1] Group 2 - Among the top circulating shareholders of Yutian Guanjia, a fund under China Europe Fund, specifically the China Europe Enjoy Life Mixed A Fund (010336), entered the top ten shareholders in the third quarter, holding 408,500 shares, which is 2.3% of the circulating shares [2] - The fund has a current scale of 2.004 billion CNY and has reported a year-to-date return of 11.47%, ranking 5454 out of 8138 in its category [2] - The fund manager, Qian Yafengyun, has a tenure of 10 years and 119 days, with the best fund return during this period being 242.9% and the worst being -25.66% [3]

Core Viewpoint - On November 18, Haisun Pharmaceutical experienced a decline of 5.19%, with a stock price of 65.55 CNY per share, a trading volume of 397 million CNY, a turnover rate of 7.14%, and a total market capitalization of 7.866 billion CNY [1] Company Overview - Nanjing Haisun Pharmaceutical Co., Ltd. is located at No. 1 Hengfa Road, Nanjing Economic and Technological Development Zone, Jiangsu Province, and was established on January 15, 2003, with its listing date on January 12, 2017 [1] - The company's main business involves the research, development, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Revenue Composition - The revenue composition of Haisun Pharmaceutical is as follows: - Cardiovascular drugs: 87.12% - Antibiotics: 5.69% - Active pharmaceutical ingredients and intermediates: 1.68% - Digestive drugs: 1.50% - Antiviral drugs: 1.47% - Others (supplements): 0.83% - Immune regulators: 0.80% - Other categories: 0.57% - Diuretics: 0.34% [1] Shareholder Information - Among the top ten circulating shareholders of Haisun Pharmaceutical, a fund under China Europe Fund ranks as a new entrant in the third quarter, holding 937,000 shares, which accounts for 1.14% of the circulating shares [2] - The estimated floating loss for this fund today is approximately 3.3638 million CNY [2] Fund Performance - The China Europe Enjoy Life Mixed A Fund (010336) was established on January 7, 2021, with a latest scale of 2.004 billion CNY [2] - Year-to-date return is 13.68%, ranking 5257 out of 8140 in its category; the one-year return is 12.32%, ranking 5349 out of 8057; since inception, the fund has incurred a loss of 47.66% [2] Fund Manager Information - The fund manager of China Europe Enjoy Life Mixed A is Qian Yafeng, who has a cumulative tenure of 10 years and 118 days [3] - The total asset scale of the fund is 2.496 billion CNY, with the best fund return during the tenure being 242.9% and the worst being -24.02% [3]

Group 1 - The core point of the news is that Hainan Pharmaceutical experienced a decline of 5.22% in its stock price, reaching 54.10 CNY per share, with a trading volume of 1.87 billion CNY and a turnover rate of 4.14%, resulting in a total market capitalization of 6.492 billion CNY [1] - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, is primarily engaged in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's main business revenue composition includes cardiovascular drugs at 87.12%, antibiotics at 5.69%, active pharmaceutical ingredients and intermediates at 1.68%, digestive drugs at 1.50%, antiviral drugs at 1.47%, and other categories [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, one fund under China Europe Fund, namely China Europe Enjoy Life Mixed A (010336), entered the top ten shareholders in the third quarter, holding 937,000 shares, which accounts for 1.14% of the circulating shares [2] - The fund, established on January 7, 2021, has a latest scale of 2.004 billion CNY, with a year-to-date return of 12.62%, ranking 5535 out of 8147 in its category, and a one-year return of 5.47%, ranking 6352 out of 8056 [2] - The fund manager of China Europe Enjoy Life Mixed A is Qian Yafeng, who has a cumulative tenure of 10 years and 112 days, with the best fund return during his tenure being 242.9% and the worst being -26.19% [3]

Group 1 - The core viewpoint of the news is that Haisun Pharmaceutical has seen a significant stock price increase, with a 5.07% rise on October 29, reaching 62.83 CNY per share, and a total market capitalization of 7.54 billion CNY [1] - Haisun Pharmaceutical's stock has increased for three consecutive days, with a cumulative increase of 15.62% during this period [1] - The company, established on January 15, 2003, specializes in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] Group 2 - The main revenue composition of Haisun Pharmaceutical includes 87.12% from cardiovascular drugs, 5.69% from antibiotics, and smaller contributions from other categories such as digestive (1.50%) and antiviral (1.47%) drugs [1] - Among the top ten circulating shareholders, a fund under China Europe Fund, specifically the China Europe Enjoy Life Mixed A (010336), has entered the list, holding 937,000 shares, which is 1.14% of the circulating shares [2] - The fund has achieved a year-to-date return of 12.53% and a one-year return of 9.4%, ranking 5532 out of 8155 and 5727 out of 8031 in its category, respectively [2]

Group 1 - The core viewpoint of the news is that Yutian Guanjia (301173.SZ) has reported an increase in institutional holdings, indicating growing investor confidence in the company [1] - As of October 28, 2025, a total of 9 institutional investors hold shares in Yutian Guanjia, with a combined holding of 51.918 million shares, representing 59.11% of the total share capital [1] - Compared to the previous quarter, the total institutional holding percentage has increased by 0.33 percentage points [1] Group 2 - In the public fund sector, there was an increase in holdings from one public fund, specifically the China Europe Enjoy Life Mixed A fund, which saw an increase of 0.46% in its holdings [2] - A total of 1,976 public funds did not disclose their holdings in the current period, including funds such as Guojin Quantitative Multi-Factor A and Guojin Quantitative Selected A [2]

Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical has seen a significant increase in its stock price, rising by 5.62% to reach 56.20 yuan per share, with a trading volume of 267 million yuan and a turnover rate of 5.89%, resulting in a total market capitalization of 6.744 billion yuan [1] - Hainan Pharmaceutical, established on January 15, 2003, and listed on January 12, 2017, is primarily engaged in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The company's main business revenue composition includes cardiovascular drugs at 87.12%, antibiotics at 5.69%, active pharmaceutical ingredients and intermediates at 1.68%, digestive drugs at 1.50%, antiviral drugs at 1.47%, and other categories [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, a fund under China Europe Fund has entered the top ten, specifically the China Europe Enjoy Life Mixed A Fund (010336), which holds 937,000 shares, accounting for 1.14% of the circulating shares [2] - The China Europe Enjoy Life Mixed A Fund was established on January 7, 2021, with a latest scale of 2.048 billion yuan, achieving a year-to-date return of 12.73% and a one-year return of 10.24% [2] - The fund manager, Qian Yafengyun, has a cumulative tenure of 10 years and 96 days, with the fund's total asset scale at 2.578 billion yuan, achieving a best return of 242.9% and a worst return of -26.25% during the tenure [3]